OraSure Submits Rapid Molecular Self-Test and At-Home Urine Collection Device for FDA Clearance
Summary
OraSure Technologies announced the submission of its rapid molecular self-test for CT/NG and its Colli-Pee™ at-home urine collection device for STIs to the FDA for clearance, marking a significant advancement in its diagnostic product pipeline.
Key Events
-
FDA Submissions for Key Diagnostic Products
OraSure Technologies submitted two separate applications to the U.S. Food and Drug Administration (FDA) for clearance of its rapid molecular self-test for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) and its Colli-Pee™ at-home urine collection device for sexually transmitted infections (STIs).
-
CT/NG Self-Test Targets Large Market
The rapid molecular self-test for CT/NG is designed for over-the-counter usage, provides results in approximately 30 minutes, and addresses a total market estimated at over $1.5 billion, aiming to expand access to testing beyond centralized laboratories.
-
Colli-Pee™ Device Enhances At-Home Collection
The Colli-Pee™ at-home urine collection device is designed for multiple STI indications, aligning with patient preferences for private and convenient diagnostic testing and strengthening OraSure's position in novel collection devices.
-
Strategic Move Towards Decentralized Diagnostics
These submissions reflect meaningful progress on OraSure's innovation roadmap, bringing the company closer to its vision of decentralizing diagnostics and connecting people to more accessible, convenient, private, and personalized care.
Analysis
OraSure Technologies has taken a significant step in its product development pipeline by submitting two key diagnostic products to the FDA for clearance. The rapid molecular self-test for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) targets a substantial addressable market of over $1.5 billion and is designed for convenient over-the-counter use, aligning with the company's strategy to decentralize diagnostics. The Colli-Pee™ at-home urine collection device further enhances their offerings for sexually transmitted infection (STI) testing, catering to patient preferences for privacy and convenience. These submissions, while not approvals, represent critical milestones that could significantly expand OraSure's market reach and revenue potential if cleared, positioning the company as a leader in accessible diagnostic solutions.
At the time of this filing, OSUR was trading at $2.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $170.7M. The 52-week trading range was $2.08 to $4.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.